Navigation Links
Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
Date:11/3/2010

SEATTLE, Nov. 3, 2010 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has been awarded non-taxable grants totaling approximately $1.7 million under the Qualifying Therapeutic Discovery Project (QTDP) included in the Patient Protection and Affordable Health Care Act of 2010.

To be eligible to receive a grant award under the QTDP program, projects must show reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute disease and conditions; to reduce long-term health care costs in the United States; or to significantly advance the goal of curing cancer within 30 years. Grant applications were reviewed by both the Treasury Department and the Department of Health and Human Services.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
6. Omeros Appoints New Vice President of Clinical Development
7. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
8. Omeros Commences Initial Public Offering of Common Stock
9. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
10. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
11. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... overseeing all service activities supporting EDETEK’s products including training, implementation, support, and client ... to his new role. He has previously held leadership roles for service providers ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition ... just announced two more sessions of its “From the Helm” Webinar Series. ... world of online templates for design control exercises. Led by David Cronin, Cognition’s ...
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
(Date:6/15/2017)... ... June 15, 2017 , ... Adam Equipment, a leading provider ... a lab workstation. The guide outlines the procedure in four simple steps, using ... AVT anti-vibration table, OIML/ASTM certified weights, and Adam DU specialized software. , A ...
Breaking Biology Technology:
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):